1. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial;Bresalier;N Engl J Med,2005
2. Prepared testimony, Raymond V. Gilmartin, president, chairman and chief executive officer, Merck and Co., Inc before the United States Committee on Finance November 18;Gilmartin,2004
3. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids;Catella-Lawson;J Pharmacol Exp Ther,1999
4. Final Results of an Analysis of the Incidence of Cardiovascular SAEs in the Phase IIb/III VIOXX Osteoarthritis Clinical Trials, February 2, 1998, MRK-NJ0066804 at MRK- NJ0066808.
5. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program;Weir;Am Heart J,2003